Belongs to

• Solid Tumor Oncology Division

Types of Work

["2019"]

[[["Meeting Abstracts",210],["Journal Articles",188],["Reviews",5],["Editorials",3],["Research Letters",3],["Book Sections",1]]]

[410]

Popular keywords

• adult
• aged
• article
• controlled study
• female
• gene mutation
• human
• major clinical study
• male
• priority journal

Recent Works

1. Camonsertib in DNA damage response-deficient advanced solid tumors: Phase 1 trial results

   Journal Article

   Yap, T. A.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; Plummer, R.; more...
   Nature Medicine (2023)

   Fulltext@MSK | Save
2. Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: Results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial

   Journal Article

   Schram, A. M.; Colombo, N.; Arrowsmith, E.; Narayan, V.; Yonemori, K.; Scambia, G.; Zelnak, A.; Bauer, T. M.; Jin, N.; Ulahannan, S. V.; more...
   JAMA Oncology (2023)

   Fulltext@MSK | Save
3. Avelumab plus talazoparib in patients with advanced solid tumors: The JAVELIN PARP Medley nonrandomized controlled trial

   Journal Article

   Yap, T. A.; Bardia, A.; Dvorkin, M.; Galsky, M. D.; Beck, J. T.; Wise, D. R.; Karyakin, O.; Rubovszky, G.; Kislov, N.; Rohrberg, K.; more...
   JAMA Oncology (2023)

   Fulltext@MSK | Save